OLIGOPIN®: new clinical study shows quality of life improvements in patients with type 2 diabetes

Improving the quality of life of people suffering from type 2 diabetes, without substituting for medical treatment: this was the aim of Dr Rafraf’s university team in its clinical study of 46 subjects suffering from type 2 diabetes associated with microalbuminuria and supplemented with Oligopin®. (1)

Type 2 diabetes is the most widespread form of diabetes in the world (90%). It is characterised by chronic hyperglycaemia, i.e. an excessively high level of sugar in the blood, due to insulin resistance. It is often associated with being overweight.(2)

Oligopin® restores normal albuminuria
In this randomised double-blind study (3), versus placebo, it was shown that supplementation with 100mg of Oligopin®/day for 8 weeks reduced the UACR (Urinary Albumin to creatinine ratio) by 34.2%, and restored normal microalbuminuria values (<30mg/24h).

Oligopin® helps to maintain the body’s balance
By helping patients regain normal albuminuria (< 30 mg/24h), Oligopin® helps maintain homeostasis.

The daily supplementation with Oligopin® also demonstrated favorable effects on glycemic control, serum VCAM-1 as well as total cholesterol concentrations, which may be helpful in the control of diabetes complications.


  • Decrease of FBS (fasting blood sugar) by 15.2%
  • Decrease of HbA1c (Glycosylated hemoglobin) by 10.7%
  • Decrease of VCAM-1 (Vascular Cell Adhesion Molecule) by 26.8%

Oligopin® is a French pine bark extract titrated in low molar mass OPC and manufactured in France by DRT, a company of the Firmenich group.
Contact: info@purextract.fr


(1) As a reminder, microalbuminuria is defined by the presence of 30 to 300mg of albumin in the urine produced in 24 hours. This condition may lead to diabetic nephropathy
(2) https://www.who.int/fr/news-room/fact-sheets/detail/diabetes
(3) Effect of French maritime pine bark extract supplementation on metabolic status and serum vascular cell adhesion molecule-1 levels in patients with type 2 diabetes and microalbuminuria
Complementary Therapies in Medicine 58 (2021) 102689